Abstract
Background: Although propranolol has been documented to be useful in treatment of neuroleptic-induced akathisia, preliminary anecdotal reports on the efficacy of nadolol in treatment of this condition are contradictory. Method: To evaluate the efficacy of nadolol in treatment of this condition, a double-blind, placebo-controlled trial was conducted in 20 psychiatric inpatients. Patients with akathisia of at least moderate severity were randomly assigned to receive nadolol 40 to 80 mg/day or placebo. Patients were rated daily for 4 days, then every other day for 15 days by means of the Extrapyramidal Symptom Rating Scale. Results: No significant differences were found between or within groups in subjective restlessness scores. In objective akathisia scores, there were no significant differences between groups; however, beginning at Day 9, both groups showed significant improvement compared with Day 1. There was no difference between groups in number of responders. Conclusions: The authors' data do not support the efficacy of nadolol in the treatment of neuroleptic-induced akathisia and do not provide support for a peripheral site of action for β-blockers in treatment of this condition.
| Original language | English |
|---|---|
| Pages (from-to) | 255-260 |
| Number of pages | 6 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 52 |
| Issue number | 6 |
| State | Published - Jan 1 1991 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
- Clinical Psychology
Cite this
A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. / Wells, B. G.; Cold, J. A.; Marken, P. A.; Brown, C. S.; Chu, C. C.; Johnson, R. P.; Nasdahl, C. S.; Ayubi, M. A.; Knott, D. H.; Arheart, Kristopher.
In: Journal of Clinical Psychiatry, Vol. 52, No. 6, 01.01.1991, p. 255-260.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia
AU - Wells, B. G.
AU - Cold, J. A.
AU - Marken, P. A.
AU - Brown, C. S.
AU - Chu, C. C.
AU - Johnson, R. P.
AU - Nasdahl, C. S.
AU - Ayubi, M. A.
AU - Knott, D. H.
AU - Arheart, Kristopher
PY - 1991/1/1
Y1 - 1991/1/1
N2 - Background: Although propranolol has been documented to be useful in treatment of neuroleptic-induced akathisia, preliminary anecdotal reports on the efficacy of nadolol in treatment of this condition are contradictory. Method: To evaluate the efficacy of nadolol in treatment of this condition, a double-blind, placebo-controlled trial was conducted in 20 psychiatric inpatients. Patients with akathisia of at least moderate severity were randomly assigned to receive nadolol 40 to 80 mg/day or placebo. Patients were rated daily for 4 days, then every other day for 15 days by means of the Extrapyramidal Symptom Rating Scale. Results: No significant differences were found between or within groups in subjective restlessness scores. In objective akathisia scores, there were no significant differences between groups; however, beginning at Day 9, both groups showed significant improvement compared with Day 1. There was no difference between groups in number of responders. Conclusions: The authors' data do not support the efficacy of nadolol in the treatment of neuroleptic-induced akathisia and do not provide support for a peripheral site of action for β-blockers in treatment of this condition.
AB - Background: Although propranolol has been documented to be useful in treatment of neuroleptic-induced akathisia, preliminary anecdotal reports on the efficacy of nadolol in treatment of this condition are contradictory. Method: To evaluate the efficacy of nadolol in treatment of this condition, a double-blind, placebo-controlled trial was conducted in 20 psychiatric inpatients. Patients with akathisia of at least moderate severity were randomly assigned to receive nadolol 40 to 80 mg/day or placebo. Patients were rated daily for 4 days, then every other day for 15 days by means of the Extrapyramidal Symptom Rating Scale. Results: No significant differences were found between or within groups in subjective restlessness scores. In objective akathisia scores, there were no significant differences between groups; however, beginning at Day 9, both groups showed significant improvement compared with Day 1. There was no difference between groups in number of responders. Conclusions: The authors' data do not support the efficacy of nadolol in the treatment of neuroleptic-induced akathisia and do not provide support for a peripheral site of action for β-blockers in treatment of this condition.
UR - http://www.scopus.com/inward/record.url?scp=0025819976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025819976&partnerID=8YFLogxK
M3 - Article
C2 - 1676029
AN - SCOPUS:0025819976
VL - 52
SP - 255
EP - 260
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
SN - 0160-6689
IS - 6
ER -